In 1928, Alexander Fleming's accidental discovery of penicillin in a London laboratory ushered in a new era of medicine. The mould that contaminated his Petri dish turned out to produce a bacteria-killing compound, later purified by Howard Florey and Ernst Chain into one of the world's first antibiotics. For nearly a century, these 'wonder drugs' have transformed once-fatal infections into manageable conditions. But that progress is now under threat.
Antimicrobial resistance (AMR) is the phenomenon by which bacteria, viruses, parasites, and fungi evolve to withstand the drugs designed to kill them. While this process occurs naturally, human behaviour—especially the misuse and overuse of antimicrobials—has dramatically accelerated it. The World Health Organization declared AMR one of the top ten global public health threats in 2019. That same year, drug-resistant infections killed at least 1.27 million people worldwide. If current trends continue, the annual death toll could reach 10 million by 2050, surpassing cancer fatalities.
Europe's Role in the AMR Crisis
Europe is not immune. Across the continent, from hospitals in Berlin to farms in Andalusia, the overprescription of antibiotics and their widespread use in livestock farming are fuelling resistance. The European Centre for Disease Prevention and Control (ECDC) estimates that more than 35,000 people die each year in the EU, Iceland, and Norway from infections resistant to antimicrobials. The economic burden is also significant, with costs related to healthcare, lost productivity, and premature death running into billions of euros annually.
National governments and EU institutions have responded with a mix of regulation, surveillance, and public awareness campaigns. The European Commission's 'One Health' action plan, launched in 2017, targets human health, animal health, and the environment as interconnected domains. Several member states, including Sweden and the Netherlands, have already achieved notable reductions in antibiotic use in agriculture through strict guidelines and voluntary agreements. France, which historically had high consumption rates, has introduced financial incentives for doctors to prescribe fewer antibiotics.
Yet challenges remain. A 2023 report from the European Court of Auditors found that progress across the EU is uneven, with some countries still lacking robust national action plans. The auditors also noted that data on antibiotic use in animals is not always comparable, complicating efforts to track trends. Meanwhile, the pipeline for new antibiotics is thin: only a handful of novel drugs have been approved in the past decade, and few are in late-stage development.
Living with Resistance
For patients, the consequences are deeply personal. In a recent feature, a patient's story of powerlessness and perseverance highlighted the emotional and physical toll of a drug-resistant infection. Simple surgeries become risky, and common ailments like urinary tract infections can turn life-threatening. The experience underscores why prevention is as critical as cure.
Good hygiene and sanitation are frontline defences. Hospitals, farms, and sewage-treatment plants can act as breeding grounds for dangerous pathogens if not properly managed. In several European cities, including Copenhagen and Amsterdam, wastewater surveillance is being used to detect resistant bacteria early. Such measures, combined with vaccination campaigns and better infection control, can reduce the need for antimicrobials in the first place.
Innovation and Policy Gaps
Addressing AMR also requires economic incentives. The current market model does not reward the development of new antibiotics, which are typically used sparingly to preserve their effectiveness. Several European countries, including the UK and Germany, have experimented with 'subscription' models that pay pharmaceutical companies a fixed annual fee for access to certain antibiotics, regardless of how much is used. The European Commission has proposed a similar scheme at the EU level, but negotiations are ongoing.
Research into alternatives, such as bacteriophages—viruses that target specific bacteria—is gaining traction in places like Georgia and Poland, where phage therapy has a long history. However, regulatory hurdles and limited funding have slowed widespread adoption. The EU's Horizon Europe programme has allocated significant resources to AMR research, but experts argue that more coordinated action is needed.
The stakes could not be higher. Without effective antimicrobials, modern medicine as we know it would unravel. Routine procedures like hip replacements, chemotherapy, and caesarean sections would become perilous. Europe, with its advanced healthcare systems and regulatory frameworks, has both the responsibility and the capacity to lead the global fight against AMR. But time is running out.
